|
|
Article: Rigel Presents Positive Results of R112 Clinical Trial for the Treatment of Allergic Rhinitis; Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting.
- Article from:
- PR Newswire
- Article date:
- March 18, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Rigel Pharmaceuticals, Inc. today announced the presentation of clinical data for R112, the company's lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.
The presentation entitled, "The Effect of a Novel Inhibitor of Mast Cell Activation on Mediators, Symptoms and Nasal Patency in Allergic Rhinitis," reports data from the Phase I/II study, evaluating R112 for the treatment of allergic rhinitis. The study ...